Helping Young People With Testicular Cancer Using Virtual and Extended Reality (TRANSCEND-XR)
Addressing TesticulaR cANcer Unmet Supportive CarE NeeDs in Adolescents and Young Adults Using eXtended Reality
TRANSCEND-XR is a European research project designed to better support adolescents and young adults who have been cured of testicular cancer. Even after treatment has ended, many young people continue to face physical, psychological, or social difficulties that are often poorly understood and insufficiently addressed.
The project aims to develop an innovative digital tool using extended reality (XR) to help these young people better understand the potential long-term effects of the disease and its treatments, recognize signs that require medical attention, and become more active participants in their own health follow-up.
TRANSCEND-XR first includes a pilot phase to test feasibility and improve the tool, followed by a larger clinical study comparing its use with usual medical follow-up. Researchers will assess, in particular, its impact on patients' knowledge, quality of life, and ability to seek help.
The ultimate goal is to sustainably improve information, autonomy, and well-being among young survivors of testicular cancer through a digital approach tailored to their needs and daily practices.
調査の概要
詳細な説明
Testicular cancer is a rare cancer, but it mainly affects adolescents and young adults. Today, thanks to the effectiveness of treatments, the vast majority of patients are cured. However, even after treatment has ended, many young people continue to live with long-term consequences, known as "late effects." These effects can vary widely and may include persistent fatigue, pain, hormonal or sexual problems, psychological difficulties such as anxiety or stress, as well as impacts on social life, relationships, education, or professional life.
These difficulties are often poorly understood by patients themselves, sometimes insufficiently addressed during medical follow-up, and may last for several years. Many young people feel inadequately informed, isolated, or unsure about when and how to seek help. Although essential, standard medical follow-up does not always fully address all of these supportive care needs.
It is within this context that the TRANSCEND-XR project was created. TRANSCEND-XR is a European research project coordinated by Gustave Roussy, aiming to develop and evaluate an innovative digital tool based on extended reality (XR) for adolescents and young adults treated for testicular cancer.
TRANSCEND-XR seeks to help young survivors better understand their disease and the treatments they have received, learn about potential long-term effects, recognize symptoms that require medical attention, and adopt health-promoting behaviors. The tool also aims to strengthen their autonomy, confidence, and ability to take an active role in their own follow-up care.
The project is carried out in two main phases. A first pilot study, conducted with a small number of participants across several countries, assesses the feasibility, usability, and acceptability of the tool and allows it to be improved based on patient feedback. A second phase involves a larger clinical study comparing young people who use the TRANSCEND-XR tool with others who receive standard follow-up care only. Researchers will evaluate, in particular, the impact on patients' knowledge, quality of life, supportive care needs, help-seeking behavior, and engagement in long-term follow-up.
Beyond medical outcomes, TRANSCEND-XR also focuses on user experience, digital accessibility, ethical considerations, and equity, in order to offer a solution that is truly adapted to young people's needs and everyday practices.
In summary, TRANSCEND-XR aims to sustainably improve information, well-being, and quality of life for young survivors of testicular cancer, using innovative digital tools to better address the challenges of life after cancer.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前：Anna Patrikidou
- 電話番号：+33142114211
- メール：anna.patrikidou@gustaveroussy.fr
研究連絡先のバックアップ
- 名前：Adeline Salasc
- メール：adeline.salasc@gustaveroussy.fr
参加基準
適格基準
就学可能な年齢
- 子
- 大人
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Any person assigned male at birth who is diagnosed with stage I-III TC (germ cell tumour of the testicles).
- Aged between 15 and 39 years at the time of study inclusion.
- Completed curative treatment comprising of at least one standard treatment modality (surgery, chemotherapy and/or radiotherapy) for treatment of their cancer. A maximum of 9 months from the end of curative treatment will be allowed.
Permitted treatment modalities:
- Localised disease: orchiectomy with or without chemotherapy and/or radiotherapy.
- Metastatic disease: orchiectomy and chemotherapy or radiotherapy or retroperitoneal surgery, or a combination of aforementioned treatments. First-line treatment only allowed.
- Willing and able to provide a valid and signed informed consent and/or assent, as appropriate.
- ECOG performance status 0-2.
- Patients accept to use personal smartphone
- Patients able to read and understand the local language
Exclusion Criteria:
- Non-testicular germ cell tumours (e.g., mediastinal primary or retroperitoneal primary tumours).
- Non-germ cell TC.
- Previous chemotherapy, radiotherapy, or surgery for TC other than that allowed in IC 4.
- History of contralateral TC.
- Any illness that would prevent the AYA TC survivor from giving a valid and signed informed consent, as assessed by the investigator.
- Any illness that might be exacerbated by the use of an XR digital tool, as assessed by the investigator, including history of severe motion sickness, brain lesions and epilepsy.
- Uncontrolled medical condition such as uncontrolled infection, uncontrolled diabetes mellitus or cardiac disease (including but not limited to grade 2 or higher cardiac failure, arrythmia, unstable angina, history of myocardial infract in the 6 months which, in the opinion of the treating physician, would influence the assessment of long-term side effect of TC treatment.
- AYA TC survivors with a "currently active" second malignancy other than non-melanoma skin cancers, superficial non-invasive (pTa or pTis) TCC of the bladder, or intratubular germ cell neoplasia. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for ≥ 3 years.
- Chemotherapy or radiotherapy for malignant disease other than TC within the past 3 years.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：支持療法
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Intervention arm (arm I)
participants will receive, in addition to their standard of care, an educational intervention via the digital tool for a period of 6 months, followed by an additional 12 months of follow-up.
|
TRANSCEND-XR is a digital educational intervention based on extended reality (XR), designed for adolescents and young adults who have completed curative treatment for testicular cancer. It provides interactive and immersive content aimed at improving understanding of the late effects of treatment, whether physical, psychological, or social. The tool helps users recognize symptoms that require medical attention, strengthen their health knowledge, and adopt behaviors that support long-term follow-up, such as self-examination and appropriate use of healthcare services. Co-designed with patients and healthcare professionals, TRANSCEND-XR aims to enhance autonomy, confidence, and engagement of young survivors in managing their health after cancer. |
|
介入なし：Control arm (arm C)
participants will receive their standard of care, without intervention, for a period of 6 months, followed by an additional 12 months of follow-up.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pilot study: to determine the feasibility of implementing the XR digital tool in AYA survivors of testicular cancer
時間枠：after 6 months of inclusion
|
Assessed by inclusion time, engagement, no major issue with patient feedback
|
after 6 months of inclusion
|
|
pRCT (Pragmatic Randomized Controlled Trial): knowledge of the late effects of XR digital tool in AYA survivors of testicular cancer
時間枠：12 months follow-up (18 months after randomization)
|
Assessed by analysis of data collected during study visits
|
12 months follow-up (18 months after randomization)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pilot study: quality of questionnaires used
時間枠：9 months after the begin of the study
|
Assessed by completion rate and number of missing responses
|
9 months after the begin of the study
|
|
pRCT (Pragmatic Randomized Controlled Trial): Health-related quality of life
時間枠：at the end of the study (5 years)
|
Assessed using the EORTC-QLQ-C30 & T26 and EQ-5D-5L questionnaires
|
at the end of the study (5 years)
|
|
pRCT (Pragmatic Randomized Controlled Trial): Supportive care needs
時間枠：at the end of the study (5 years)
|
Measured using the CaSUN questionnaire
|
at the end of the study (5 years)
|
協力者と研究者
捜査官
- 主任研究者：Anna Patrikidou、Gustave Roussy, Cancer Campus, Grand Paris
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- 2026-A00740-51
- CSET number 2026 / 4327 (その他の識別子：Gustave Roussy)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。